免疫调节剂防治脑卒中相关性感染的临床研究

Clinical effect of immunomodulators on prevention of stoke-associated infections

目的探讨免疫调节剂防治脑卒中相关性感染临床效果,以最佳的方法降低脑卒中后并发症发生,提高临床诊治水平。方法选取2010年2月-2014年1月70例脑卒中相关性感染患者为研究对象,将其随机分为两组,每组各35例;对照组患者予常规西医预防感染、营养支持等治疗,观察组患者加用免疫调节剂治疗,观察两组患者治疗后在临床效果和相关指标的差异。结果对照组治愈率为54.29%、总有效率82.86%,观察组治愈率62.86%、总有效率94.29%,两者比较差异有统计学意义(P<0.05);两组患者治疗后第3、5、7、14天C-反应蛋白比较差异有统计学意义(P<0.05);纤维蛋白原、外周血单核细胞计数、APAICHEⅡ、NIHSS、GCS评分,两组比较差异有统计学意义(P<0.05)。结论免疫调节剂能降低脑卒中相关性感染的发生,可提高临床效果,抑制炎性介质,提高生活质量。

OBJECTIVE To explore the clinical effect of immunomodulators on prevention of stroke-associated infec-tions so as to choose optimal method to reduce the incidence of complications after stroke and to improve the level of clinical diagnosis and treatment .METHODS A total of 70 patients with stroke-associated infections who were treated in the hospital from Feb 2010 to Jan 2014 were recruited as the study objects and divided into two groups , with 35 cases in each .The control group was treated with conventional western medicine and nutrition support , while the observation group was given additional immunomodulators ;the clinical effects and the related indicators were observed and compared between the two groups .RESULTS The cure rate was 54 .29% in the control group , 62 .86% in the observation group ;the total effective rate was 82 .86% in the control group ,94 .29% in the obser-vation group ,and there was significant difference between the two groups （P〈 0 .05） ;there was statistically sig-nificant difference in the level of C-reactive protein on 3rd ,5th ,7th ,or 14th day of treatment between the two groups （P〈 0 .05） ;there was difference in the fibrinogen ,peripheral blood mononuclear cell counts ,APAICHEⅡ ,NIHSS ,or GCS between the two groups （P 〈 0 .05） .CONCLUSION The immunomodulators can reduce the incidence of stroke-associated infections ,improve the clinical effect ,inhibit the inflammatory mediators ,and im-prove the quality of life .